medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 2

<< Back Next >>

Ann Hepatol 2015; 14 (2)

Transarterial chemoembolisation in intermediate-stage hepatocellular carcinoma. Survey on clinical practice in hospitals in the Madrid Region

Matilla PA, Núñez-Martínez Ó, Díaz-Sánchez A, Pons-Renedo F, Gómez-Rubio M, Polo-Lorduy B, Lledó-Navarro JL, Trapero-Marugán M, Ladero-Quesada JM, Poves-Martínez E, Ibáñez-Pinto A, Martín-Algívez AM, Lozano-Maya M, González-Alonso R, Piqueras-Alcol B, González-Moreno L, Fernández-Rodríguez C, Gea-Rodríguez F

Language: English
References: 23
Page: 207-217
PDF size: 200.92 Kb.


ABSTRACT

Background. Transarterial chemoembolisation (TACE), having demonstrated survival benefits, is the treatment of choice in intermediate-stage hepatocellular carcinoma, although there is great heterogeneity in its clinical application. Material and methods. A survey was sent to the Madrid Regional hospitals to assess applicability, indications and treatment protocols. The assessment was made overall and according to the type of hospital (groups A vs. B and C). Results. Seventeen out of 22 hospitals responded (8/8 group A, 9/ 14 group B-C). All do/indicate transarterial chemoembolisation, 13/17 at their own facilities. Eight of the 17 hospitals have multidisciplinary groups (5/8 A, 3/9 B-C). Nine hospitals perform › 20 procedures/year (7 group A), and 6 from group B-C request/perform ‹ 10/year. It is performed on an “on-demand” basis in 12/17. In 5 hospitals, all the procedures use drug-eluting beads loaded with doxorubicin. The average number of procedures per patient is 2. The mean time from diagnosis of hepatocellular carcinoma to transarterial chemoembolisation is ≤ 2 months in 16 hospitals. In 11/17 hospitals, response is assessed by computed tomography. Radiological response is measured without specific criteria in 12/17 and the other five hospitals (4 group A) assessed using standardised criteria. Conclusion. Uniformity among the Madrid Regional hospitals was found in the indication and treatment regimen. The use of DEB-TACE has become the preferred form of TACE in clinical practice. The differentiating factors for the more specialised hospitals are a larger volume of procedures, decision-making by multidisciplinary committees and assessment of radiological response more likely to be standardised.


REFERENCES

  1. Forner A, Ayuso C, Real MI, Sastre J, Robles R, Sangro B, Varela M, et al. Conferencia de consenso. Diagnóstico y tratamiento del carcinoma hepatocelular. Med Clin 2009; 132: 272-87.

  2. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2002;56: 908-43.

  3. Bruix J, Sherman M. AASLD Practice Guideline. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-2.

  4. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.

  5. Llovet JM, Bourroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.

  6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.

  7. Bolondi L, Burroughs A, Dufour J-F, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348-59.

  8. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-20.

  9. Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, Giampalma E, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol 2012; 57: 1258-67.

  10. Gaba RC. Chemoembolization practice patterns and technical methods among interventional radiologists: Results of an online survey. AJR 2012; 198: 692-9.

  11. Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013; 11: 604-11.

  12. Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC, et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): Technical recommendations. Cardiovasc Intervent Radiol 2011; 35: 980-5.

  13. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, et al. Prospective randomized study of Doxorubicin- Eluting-Bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.

  14. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46(3): 474-81.

  15. Burrell M, Reig M, Forner A, Barrufet M, Rodríguez de Lope C, Tremosini S, Ayuso C, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using DC Beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-5.

  16. Bargelli I, Florio F, Golfieri R, Grosso M, Lauretti DL and Cioni R. Trends in utilization of transarterial treatments for hepatocellular carcinoma: Results of a survey by the Italian Society of interventional Radiology. Cardiovas Intervent Radiol 2014; 37: 438-44.

  17. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, et al. The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013; 57: 2261-73.

  18. Minami Y, Kudo M. Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: Ultrasonography, CT and MR imaging. Oncology 2013; 84(suppl. 1): 58-63.

  19. Bruix J, Reig M, Rimola J, Forner A, Burrel M, Vilana R, Ayuso C. Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques. Hepatology 2011; 54: 2238-44.

  20. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.

  21. Dufour JF, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho RT. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Ann Oncol 2013; 24(Suppl. 2): ii24-9.

  22. Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X, Han G. Combination therapy of sorafenib and TACE for unresectable HCC: A systematic review and meta-analysis. PLoS One 2014; 9: e91124.

  23. Zhang L, Hu P, Chen X, Bie P. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: A meta-analysis. PLoS One 2014; 9: e100305.




2020     |     www.medigraphic.com